140 related articles for article (PubMed ID: 38135609)
1. Evidence-based management of primary and secondary CNS lymphoma.
Khwaja J; Nayak L; Cwynarski K
Semin Hematol; 2023 Nov; 60(5):313-321. PubMed ID: 38135609
[TBL] [Abstract][Full Text] [Related]
2. Management of primary and secondary CNS lymphoma.
Khwaja J; Cwynarski K
Hematol Oncol; 2023 Jun; 41 Suppl 1():25-35. PubMed ID: 37294958
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the diagnosis and the treatment of primary CNS lymphoma.
Rachdi A; Hernandez-Tost H; Herzi D; Morales-Martinez A; Hernández-Verdin I; Houillier C; Alentorn A; Hoang-Xuan K
Rev Neurol (Paris); 2023 Jun; 179(5):481-489. PubMed ID: 37045615
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
6. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
[TBL] [Abstract][Full Text] [Related]
8. Advances in therapeutic strategies for primary CNS B-cell lymphomas.
Ramadan S; Radice T; Ismail A; Fiori S; Tarella C
Expert Rev Hematol; 2022 Apr; 15(4):295-304. PubMed ID: 35467473
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
Illerhaus G; Kasenda B; Ihorst G; Egerer G; Lamprecht M; Keller U; Wolf HH; Hirt C; Stilgenbauer S; Binder M; Hau P; Edinger M; Frickhofen N; Bentz M; Möhle R; Röth A; Pfreundschuh M; von Baumgarten L; Deckert M; Hader C; Fricker H; Valk E; Schorb E; Fritsch K; Finke J
Lancet Haematol; 2016 Aug; 3(8):e388-97. PubMed ID: 27476790
[TBL] [Abstract][Full Text] [Related]
10. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
Epperla N; Reljic T; Chowdhury SM; Ferreri AJM; Kumar A; Hamadani M
Hematol Oncol; 2023 Feb; 41(1):88-96. PubMed ID: 36192141
[TBL] [Abstract][Full Text] [Related]
11. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Oh DH; Chua N; Street L; Stewart DA
Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
14. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Ferreri AJM; Doorduijn JK; Re A; Cabras MG; Smith J; Ilariucci F; Luppi M; Calimeri T; Cattaneo C; Khwaja J; Botto B; Cellini C; Nassi L; Linton K; McKay P; Olivieri J; Patti C; Re F; Fanni A; Singh V; Bromberg JEC; Cozens K; Gastaldi E; Bernardi M; Cascavilla N; Davies A; Fox CP; Frezzato M; Osborne W; Liberati AM; Novak U; Zambello R; Zucca E; Cwynarski K;
Lancet Haematol; 2021 Feb; 8(2):e110-e121. PubMed ID: 33513372
[TBL] [Abstract][Full Text] [Related]
15. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
18. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
Ferreri AJ; Donadoni G; Cabras MG; Patti C; Mian M; Zambello R; Tarella C; Di Nicola M; D'Arco AM; Doa G; Bruno-Ventre M; Assanelli A; Foppoli M; Citterio G; Fanni A; Mulè A; Caligaris-Cappio F; Ciceri F
J Clin Oncol; 2015 Nov; 33(33):3903-10. PubMed ID: 26282634
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
[TBL] [Abstract][Full Text] [Related]
20. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
